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Aspirin therapy is widely used in patients with arterial 
disease to prevent platelet aggregation. Currently aspirin 
therapy is monitored using platelet aggregation to measure the 
dose-response curve to diverse platelet activators including 
adrenaline, ADP, arachidonic acid and collagen.
 Thrombo-elastography measures the shear elastic strength 
of a clot and gives information on the clotting process from its 
initiation to fibrinolysis.1,2 The thrombo-elastogram is currently 
used primarily in the context of liver transplantation in order 
to measure the fibrinogen output of the graft.2,3 
Multiple parameters are measured by the thrombo-
elastogram (Fig. 1), which gives information about various 
properties of the clot (Table I).
The measure of maximal amplitude of a clot has been shown 
to correlate best with platelet number and function.
The purpose of this study was to assess the effect of low-
dose aspirin therapy on the parameters of the thrombo-
elastogram and to compare these results with platelet 
aggregometry.
Methods
This study was approved by the Ethics Committee of the 
University of the Witwatersrand.
Twenty-five healthy subjects (mean age 53 years) with no 
history or signs of cardiovascular disease were recruited from 
among colleagues in the laboratory. Thrombo-elastograms 
were performed at baseline on a sub-population (N=11) using 
the Haemoscope Corporation TEG Hemostasis analyser. The 
volunteers were treated with Ecotrin (coated aspirin) 75 mg 
for 7 days. A second thrombo-elastogram was performed in 
conjunction with platelet aggregation studies on samples from 
selected patients (N=13) after 7 days. 
Thrombo-elastography
Approximately 1 ml of fresh blood was taken, analysed in its 
original state and then activated with arachidonic acid (AA) 
and kaolin. Heparinase was added to the kaolin preparation 
to neutralise the effects of original heparins which may have 
altered the thrombo-elastogram readings. A subpopulation 
were of subjects was re-analysed 2 hours later to exclude time 
as a confounding variable in analysis. Appropriate controls 
were utilised according to the manufacturer’s instructions.
Platelet aggregometry
Platelet aggregometry was performed using the ON Helena 
Aggregometer. The citrated blood was separated into platelet-
rich plasma and then activated using the following reagents 
in two concentrations according to the manufacturer’s 
instructions:
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To assess the utility of the thrombo-elastogram in monitoring 
of aspirin therapy 25 healthy volunteers were selected and 
given low-dose aspirin therapy. Thrombo-elastography and 
platelet aggregometry were conducted at baseline and 1 week 
later. After 1 week of aspirin therapy, thrombo-elastogram 
data failed to demonstrate a significant change in the clotting 
profile. Platelet aggregometry identified significant changes in 
the clotting profile in response to stimulation with arachidonic 
acid, adrenaline and ADP.
We conclude that thrombo-elastography may not have utility 
in monitoring of response to aspirin.
S Afr Med J 2007; 97: 1289-1291.
Fig. 1 Diagram of thrombo-elastogram.
The measure of maximal amplitude of a clot has been shown to correlate best with platelet
number and function.
The purpose of this study was to assess the effect of low-dose aspirin therapy on the
parameters of the thrombo-elastogram and to compare these results with platelet
aggregometry.
Methods
This study was approved by the Ethics Committee of the University of the Witwatersrand.
Twenty-five healthy subjects (mean age 53 years) with no history or signs of cardiovascular
disease were recruited from among colleagues in the laboratory. Thrombo-elastograms were
performed at baseline on a sub-population (N=11) using the Haemoscope Corporation TEG
Hemostasis analyser. The volunteers were treated with Ecotrin (coated aspirin) 75 mg for 7
days. A second thrombo-elastogram was performed in conjunction with platelet aggregation
studies on samples from selected patients (N=13) after 7 days.
Thrombo-elastography
Approximately 1 ml of fresh blood was taken, analysed in its original state and then
activated with arachidonic acid (AA) and kaolin. Heparinase was added to the kaolin
preparation to neutralise the effects of original heparins which may have altered the
thrombo-elastogram readings. A subpopulation were of subjects was re-analysed 2 hours
later to exclude time as a confounding variable in analysis. Appropriate controls were
utilised according to the manufacturer’s instructions.
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Fig. 1. Diagram of thrombo-elastogram.
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Response to the reagents was measured as a percentage of 
platelet aggregation and reported as normal, reduced or flat.
Results
Analysis was conducted using a two-factor analysis of variance 
(ANOVA) without replication. 
Thrombo-elastogram analysis failed to show any significant 
difference between measured parameters at baseline and 1 
week later at a significance level of p=0.05 (Tables II and III). 
A decrease in maximal amplitude was noted consistently 
between the pre-aspirin and post-aspirin samples, but this 
failed to reach significance (p=0.09).
Analysis of the same data with platelet aggregometry 
showed a highly significant reduction of platelet aggregation 
in response to activation with arachidonic acid (p=0.000), 
adrenaline (p=0.001) and ADP (p=0.000), but no significant 
response to collagen. In only 1 patient did platelet 
aggregometry demonstrate no response to arachidonic acid – in 
this case, aspirin resistance was suspected. This patient failed 
to show a significant change on thrombo-elastography.
Discussion
Maximal amplitude is considered to be the most sensitive 
parameter for assessment of platelet function in thrombo-
elastography. The maximal amplitude is dependent on the 
strength of the clot following initial fibrin formation – this 
strength is almost entirely dependent on the interaction 
between the GP IIb/IIIa receptors on platelets and platelet 
aggregation which plays an integral part in this interaction. 
Previous reports have shown mixed data with regard to the 
decreased MA in response to aspirin therapy – certain authors 
demonstrated that in the setting of thrombocytopenia, this 
measurement was a sensitive measure of platelet function,4 in 
particular in the context of pre-existing vascular bed damage 
and reperfusion injury.3 A previous study on healthy controls 
given low-dose aspirin failed to show a significant change 
in the maximal amplitude.5 Our study concurred with these 
Reagent: high concentration   Reagent: low concentration
Arachidonic acid high –   Arachidonic acid low –  
1.5 mM    0.187 mM
ADP high – 2 mM   ADP low – 0.1 mM
Adrenaline high – 10 mM  Adrenaline low – 0.05 mM
Collagen high – 2 mM   Collagen low – 0.02 mM
Table I. Properties of the clot measured by the thrombo-elastogram
Reaction time  Latency to initial fibrin formation
K Measure of speed taken to reach clot stability (measure of clot kinetics)
Angle (α) Speed of fibrin build-up and cross-linking (fibrinogen level)
Maximal amplitude (MA) Measure of peak strength of a clot (representative of platelet aggregation)
LY30 Measure of the loss of clot strength after 30 minutes (clot lysis)
Table II. Thrombo-elastogram analysis before aspirin therapy 
                         Arachidonic acid Kaolin
Sample No. R value K value (min)
Angle 
(deg)
MA 
(mm) R value
K value 
(min)
Angle 
(deg)
MA 
(mm)
         
C040A 0.8 1.5 71.6 63.7 11.8 6.7 27.0 43.5
C041A 0.6 1.8 67.6 50.3 14.4 11.2 18.2 36.4
C042A 0.8 2.0 65.4 50.7 42.4    
C045A 1.1 5.0 43.7 25.6 15.4 11.8 19.5 44.0
C046A 1.4 4.2 45.4 33.5 22.0  4.7 8.1
C049A 0.6 1.7 70.2 51.4 21.3 21.7 10.5 23.8
C052A 0.7 1.4 72.6 59.1 18.1 9.0 22.6 44.3
C053A 0.7 1.8 68.7 62.9 22.0 11.3 18.2 28.7
C054A 0.7 1.6 70.5 59.8 14.8 8.5 24.2 41.1
C055A 0.6 1.3 74.1 63.4 13.3 9.7 22.0 45.3
C056A 0.8 1.5 71.1 60.4 32.3  3.6 6.9
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findings – despite evidence of aspirin response on platelet 
aggregometry, there was no significant change in parameters 
measured using thrombo-elastography. Limitations of this 
study were the small sample size and the short period of the 
intervention. These data show that it is not possible to consider 
thrombo-elastography for routine monitoring of aspirin 
therapy.
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Table III. Thrombo-elastogram analysis after aspirin therapy
                        Arachidonic acid Kaolin 
Sample No. R value
K value 
(min)
Angle
(deg)
MA 
(mm) R value
K value 
(min)
Angle 
(deg)
MA 
(mm)
C041B 0.7        
C042B 0.7 1.5 71.6 63.7 11.8 6.7 27.0 43.5
C043B 0.7 1.8 67.6 50.3 14.4 11.2 18.2 36.4
C045B 0.8 2.0 65.4 50.7 42.4    
C046B 0.6 5.0 43.7 25.6 15.4 11.8 19.5 44.0
C049B 1.1 4.2 45.4 33.5 22.0  4.7 8.1
C050B M42 0.8 1.7 70.2 51.4 21.3 21.7 10.5 23.8
C051B M48 0.8 1.4 72.6 59.1 18.1 9.0 22.6 44.3
C052B 0.7 1.8 68.7 62.9 22.0 11.3 18.2 28.7
C054B 0.7 1.6 70.5 59.8 14.8 8.5 24.2 41.1
C057B 0.7 1.3 74.1 63.4 13.3 9.7 22.0 45.3
C058B 0.8 1.5 71.1 60.4 32.3  3.6 6.9
C059B 0.7 1.7 70.2 59.1 18.1 10.45 18.85 34.9
Pg 1289-1291.indd   1291 11/27/07   3:53:30 PM
